Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2491 to 2505 of 7711 results

  1. Dupilumab for treating bullous pemphigoid [ID6479]

    Awaiting development [GID-TA11615] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Vosoritide for treating achondroplasia in people 4 months and over ID6488

    Awaiting development [GID-TA11528] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years ID 6492

    Awaiting development [GID-TA11383] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]

    Awaiting development [GID-TA11633] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years ID6484

    Awaiting development [GID-HST10063] Expected publication date: TBC

    Highly specialised technologies guidance
    Awaiting development

  6. Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis ID6487

    In development [GID-TA11628] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Iclepertin for treating cognitive impairment associated with schizophrenia ID6483

    Awaiting development [GID-TA11647] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Targeted-release budesonide for treating primary IgA nephropathy with a urine protein-to-creatinine ratio of 0.8 g/g or more (review of TA937) [ID6485]

    Awaiting development [GID-TA11662] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Cabotegravir for preventing HIV-1 in adults and young people [ID6255]

    In development [GID-TA11304] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment ID 6463

    Awaiting development [GID-TA11590] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG [ID6454]

    Awaiting development [GID-TA11592] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency ID 6466

    Awaiting development [GID-TA11583] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452

    In development [GID-TA11557] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment ID 6467

    Awaiting development [GID-TA11585] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    Awaiting development [GID-TA11535] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development